Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

61. Epilepsy

the classification of epileptic seizures and syndromes and when non- epileptic seizures are suspected. Treatment of epilepsy 2016 10. Management of epilepsy in adults with intellectual disability CR203 Browser does not support script. Browser does not support script. Improving the lives of people with mental illness Browser does not support script. CR203. Management of epilepsy in adults with intellectual disability Price: £0.00 Approved: Apr 2017 Published: May 2017 Status: current Number of pages: 49 Review (...) have questions please contact us via jon.brassey@tripdatabase.com Top results for epilepsy 1. Epilepsy Epilepsy - NICE CKS Clinical Knowledge Summaries Share Epilepsy - Summary An epileptic seizure is a transient disturbance of consciousness, behaviour, emotion, motor function, or sensation, due to abnormal electrical activity in the brain. Epilepsy is a disease of the brain defined by any of the following: At least two unprovoked seizures occurring more than 24 hours apart. One unprovoked seizure

2018 Trip Latest and Greatest

62. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and th Full Text available with Trip Pro

literature (January 2003-November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength.Several second-generation AEDs are effective for new-onset focal epilepsy. Data are lacking on efficacy in new-onset generalized tonic-clonic seizures, juvenile myoclonic epilepsy, or juvenile absence epilepsy, and on efficacy of third-generation AEDs in new-onset epilepsy.Lamotrigine (LTG) should (Level B) and levetiracetam (LEV) and zonisamide (...) (ZNS) may (Level C) be considered in decreasing seizure frequency in adults with new-onset focal epilepsy. LTG should (Level B) and gabapentin (GBP) may (Level C) be considered in decreasing seizure frequency in patients ≥60 years of age with new-onset focal epilepsy. Unless there are compelling adverse effect-related concerns, ethosuximide or valproic acid should be considered before LTG to decrease seizure frequency in treating absence seizures in childhood absence epilepsy (level B). No high

2018 EvidenceUpdates

63. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Full Text available with Trip Pro

to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength.Forty-two articles were included.The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment); rufinamide for Lennox-Gastaut syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (...) ). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent Food and Drug Administration (FDA) strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only

2018 EvidenceUpdates

64. Eslicarbazepine acetate (Zebinix) - treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy

Eslicarbazepine acetate (Zebinix) - treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy Non Submission eslicarbazepine acetate 200mg and 800mg tablets (Zebinix ® ) SMC2090 Eisai Ltd 4 May 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation eslicarbazepine acetate (Zebinix ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy in the treatment of partial (...) -onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area

2018 Scottish Medicines Consortium

65. Everolimus (Votubia) - Adjunctive treatment of patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC)

experience frequent seizures which are likely to have a severely negative impact on their physical and mental health. Many patients have neurodevelopmental problems and learning disabilities and uncontrolled epilepsy is thought to be a major contributing and exacerbating factor. • There is unmet need in the treatment of TSC-related epilepsy. Anti-epileptic medications are used as first-line treatment however it is estimated that approximately 60% of patients have seizures that are uncontrolled (...) TSC manifestations and neuropsychiatric comorbidities £41,134 Deterministic (one-way) sensitivity analysis (with PAS) Parameter ‘Lower’ value ICER ‘Upper’ value ICER Distribution of patients in epilepsy control categories – everolimus plus BSC £73,475 £22.768 % whose seizure type was secondary generalised: convulsive at 66 weeks - BSC (mean) £49,194 £9,458 Prevalence of SEGA in the 14-18 years of age group £30,784 Dominant Adverse event discontinuation - everolimus plus BSC £44,558 £15,983 % whose

2018 Scottish Medicines Consortium

66. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

as monotherapy, and how does their efficacy and tolerability compare with those of older antiepileptic drugs (AEDs)? • Clobazam (CLB) • Lacosamide • Perampanel • Topiramate (TPM) • Eslicarbazepine • Lamotrigine (LTG) • Pregabalin (PGB) • Vigabatrin (VGB • Felbamate (FBM) • Levetiracetam (LEV) • Rufinamide • Zonisamide (ZNS) • Gabapentin (GBP) • Oxcarbazepine (OXC) • Tiagabine Recommendations for monotherapy in adults with new-onset epilepsy with focal epilepsy or unclassified tonic-clonic seizures Level (...) profile precludes VGB use as first-line therapy. Level C PGB use at 150 mg/d is possibly less efficacious than LTG use at 100 mg/d. Level U Evidence is insufficient to consider GBP , OXC, or TPM instead of CBZ. Level U Evidence is insufficient to consider TPM instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic (GTC) seizures, or generalized epilepsy (GE) presenting with GTC seizures. Level U Data are lacking to support or refute use

2018 American Academy of Neurology

67. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

the seizures of most patients with idiopathic GE are easily controlled with appropriate medication, presentation of TR epilepsy is rare. It is unclear how results in this population would translate to patients with similar syndromes but with nonrefractory disease. For adult and pediatric patients with Lennox-Gastaut syndrome (LGS), are these AEDs effective as adjunctive therapy in reducing seizure frequency (compared with no adjunctive therapy)? Level Recommendation Levels A and B For LGS, RFN use should (...) ) effective as adjunctive therapy in reducing seizure frequency? Level Recommendation* Level A For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin (PGB) and perampanel (PER) are established as effective to reduce seizure frequency. Level B Lacosamide (LCM), eslicarbazepine (ESL), and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Level A Vigabatrin (VGB) and rufinamide (RFN) should be considered established

2018 American Academy of Neurology

68. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Full Text available with Trip Pro

Antiepileptic drugs as prophylaxis for postcraniotomy seizures. This is an updated version of the Cochrane Review previously published in Issue 3, 2015.The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period. Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within (...) the first month of cranial surgery. The use of antiepileptic drugs (AEDs) administered pre- or postoperatively to prevent seizures following cranial surgery has been investigated in a number of randomised controlled trials (RCTs).To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which AEDs are most effective.For the latest update we searched the following databases on 26 June 2017: Cochrane Epilepsy Group Specialized Register

2018 Cochrane

69. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Full Text available with Trip Pro

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy.In this double-blind, placebo-controlled trial conducted at 30 clinical centers, we (...) randomly assigned patients with the Lennox-Gastaut syndrome (age range, 2 to 55 years) who had had two or more drop seizures per week during a 28-day baseline period to receive cannabidiol oral solution at a dose of either 20 mg per kilogram of body weight (20-mg cannabidiol group) or 10 mg per kilogram (10-mg cannabidiol group) or matching placebo, administered in two equally divided doses daily for 14 weeks. The primary outcome was the percentage change from baseline in the frequency of drop seizures

2018 NEJM Controlled trial quality: predicted high

70. Incorporating epilepsy genetics into clinical practice: a 360°evaluation Full Text available with Trip Pro

for counseling and testing. We developed NGS panels, performing clinical interpretation with a multidisciplinary team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a genetic diagnosis was made in 34% of patients with seizure onset < 2 years, and 4% > 2 years, with turnaround time of 21 days. Pathogenic variants were seen in SCN8A, SCN2A, SCN1A (...) Incorporating epilepsy genetics into clinical practice: a 360°evaluation We evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 million. We calculated diagnostic yield, estimated clinical impact, and surveyed referring clinicians and families. We costed alternative investigational pathways for neonatal onset epilepsy. Patients with epilepsy of unknown aetiology onset < 2 years; treatment resistant epilepsy; or familial epilepsy were referred

2018 NPJ genomic medicine

71. Stiripentol add-on therapy for focal refractory epilepsy. Full Text available with Trip Pro

Stiripentol add-on therapy for focal refractory epilepsy. This is an updated version of the Cochrane review last published in 2015 (Issue 10). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam, with promising effects.To evaluate (...) -on trials of stiripentol in people with focal refractory epilepsy.Review authors independently selected trials for inclusion and extracted data. Outcomes investigated included 50% or greater reduction in seizure frequency, seizure freedom, adverse effects, treatment withdrawal and changes in quality of life.On the basis of our selection criteria, we included no new studies in the present review. Only one study was included from the earlier review (32 children with focal epilepsy). This study adopted

2018 Cochrane

72. Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study Full Text available with Trip Pro

Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study Epilepsy is a common neurological disorder in pregnancy, which is associated with increased maternal and fetal adverse outcomes. This study aimed to explore the reproductive healthcare needs of women with epilepsy before, during and after childbirth.This was a qualitative study using a content analysis method. The study population was marital women with epilepsy in reproductive age (15-45 years (...) for women with epilepsy, (2) doubt about the advantages and disadvantages of breastfeeding, (3) stigma as a block to the treatment of the postpartum depression, and (4) playing the motherhood role under the shadow of self-esteem to lack of self-esteem.In the prenatal, natal and postnatal duration, because of supportive system disruption and not receiving proper consultation, participants were often worried about not being able to get favorable conditions for safe pregnancy and controlling process

2018 Electronic physician

73. Clonazepam add-on therapy for refractory epilepsy in adults and children. Full Text available with Trip Pro

Clonazepam add-on therapy for refractory epilepsy in adults and children. Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset or generalised onset epileptic (...) seizures, when compared with placebo or another antiepileptic agent.We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).Double-blind randomised controlled studies of add-on clonazepam in people with refractory focal

2018 Cochrane

74. Epilepsy in Children After Pandemic Influenza Vaccination Full Text available with Trip Pro

Epilepsy in Children After Pandemic Influenza Vaccination To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children.Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods (...) after pandemic vaccination.In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628 new cases of epilepsy (incidence rate 6.09 per 10 000 person-years). The risk of epilepsy was not increased after vaccination: hazard ratio: 1.07; 95

2018 EvidenceUpdates

75. Rufinamide add-on therapy for refractory epilepsy. Full Text available with Trip Pro

Rufinamide add-on therapy for refractory epilepsy. Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we summarised (...) the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with focal seizures.To

2018 Cochrane

76. Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study Full Text available with Trip Pro

used Cox regression to analyze the risk of serious transport accidents between individuals with epilepsy and matched controls, and then stratified Cox regression to compare the risk during periods of medication with the risk during nonmedication period within the same individual with epilepsy. We adjusted for civil status, employment, education, living area, psychiatric disorders prior to the start of follow-up, and psychotropic medication.Compared to matched controls, individuals with epilepsy (...) Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study To investigate the association between epilepsy and antiepileptic drugs and serious transport accidents requiring emergency care or resulting in death.We identified 29,220 individuals 18 years or older with epilepsy without cerebral palsy or intellectual disability and 267,637 matched controls using Swedish registers. This nationwide cohort was followed from 2006 to 2013 for serious transport accidents. We

2018 EvidenceUpdates

77. Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) Full Text available with Trip Pro

Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality in young adults. The exact mechanisms are unknown but death often follows a generalized tonic-clonic seizure. Proposed mechanisms include seizure-related respiratory, cardiac, autonomic, and arousal dysfunction. Genetic drivers underlying SUDEP risk are largely (...) identified mutually exclusive variants in genes involved in µ-opiod signaling, gamma-aminobutyric acid (GABA) and glutamate-mediated synaptic signaling, including ARRB2, ITPR1, GABRR2, SSTR5, GRIK1, CTNAP2, GRM8, GNAI2 and GRIK5. In SUDEP patients we also identified variants in genes associated with cardiac arrhythmia, including KCNMB1, KCNIP1, DPP6, JUP, F2, and TUBA3D, which were not present in living epilepsy controls. Our data shows that genomic analysis of brain tissue resected for seizure control

2018 NPJ genomic medicine

78. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. Full Text available with Trip Pro

in mice lacking a copy of Ick.A variant, K305T (c.914A→C), cosegregated with epilepsy or polyspikes on EEG in 12 members of the family affected with juvenile myoclonic epilepsy. We identified 21 pathogenic ICK variants in 22 of 310 additional patients (7%). Four strongly linked variants (K220E, K305T, A615T, and R632X) impaired mitosis, cell-cycle exit, and radial neuroblast migration while promoting apoptosis. Tonic-clonic convulsions and polyspikes on EEG resembling seizures in human juvenile (...) Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. In juvenile myoclonic epilepsy, data are limited on the genetic basis of networks promoting convulsions with diffuse polyspikes on electroencephalography (EEG) and the subtle microscopic brain dysplasia called microdysgenesis.Using Sanger sequencing, we sequenced the exomes of six members of a large family affected with juvenile myoclonic epilepsy and confirmed cosegregation in all 37 family members. We screened an additional 310

2018 NEJM

79. Lacosamide (Vimpat) - partial-onset seizures

Lacosamide (Vimpat) - partial-onset seizures Published 12 March 2018 Statement of Advice: lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat ® ) SMC No 1324/18 UCB Pharma Limited 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation lacosamide (Vimpat ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy in the treatment of partial-onset seizures (...) with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug

2018 Scottish Medicines Consortium

80. Lacosamide (Vimpat) - treatment of partial-onset seizures with or without secondary generalisation in children

Lacosamide (Vimpat ® ) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from = 4 years of age to = 15 years of age with epilepsy. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 0318: Lacosamide (Vimpat ® ) 50 mg, 100 mg, 150 mg (...) Lacosamide (Vimpat) - treatment of partial-onset seizures with or without secondary generalisation in children Final Appraisal Recommendation Advice No: 0318 – Feb 2018 Lacosamide (Vimpat ® ) 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets; 10 mg/ml syrup; 10 mg/ml solution for infusion Limited submission by UCB Pharma Ltd. Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account

2018 All Wales Medicines Strategy Group